Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?
With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston, Massachusetts-based company engages in developing and commercializing therapies for treating cystic fibrosis (CF). Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Vertex Pharmaceuticals fits this criterion perfectly. VRTX has…
bubmagMarch 6, 2025